AstraZeneca is taking its oral GLP-1 drug into phase 3 on the back of a pair of midstage weight loss wins, despite remaining tight-lipped on how the candidate actually performed. The U.K.-based Big ...
Indexes for US equity real estate investment trusts climbed during the first week of February, outperforming the S&P 500. The Dow Jones Equity All REIT index closed the recent week up 2.32%, while the ...
Nektar Therapeutics is basking in the honeyed glow of long-term phase 2 data for its immune asset rezpegaldesleukin in atopic dermatitis, where the candidate successfully reduced the size and ...
Biomed Industries, Inc. Announces Two NA-931 Phase 3 Trials, Targeting Durable Weight Loss & Lean-Mass Preservation at JP Morgan Week 2026 Advancing NA-931, the first oral quadruple receptor ...
SAN JOSE, CA, UNITED STATES, January 19, 2026 /EINPresswire.com/ — — Biomed Industries, Inc., a clinical-stage biopharmaceutical company developing next ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results